基于加权TOPSIS法对儿科美罗培南的利用评价

Drug Use Evaluation of Meropenem Used in Pediatrics Based on Weighted TOPSIS Method

目的:探讨儿科美罗培南使用评价体系,为儿科美罗培南合理应用提供参考。方法:构建儿科美罗培南药物利用评价(DUE)标准,采用加权逼近理想解排序(TOPSIS)法对2020年10月至2021年3月我院儿科使用美罗培南的患儿临床资料进行评价。结果:共纳入130例合格病例,根据其与最佳解的相对接近程度C_(i)值进行划分,C_(i)≥0.8的合理病例38例(29.23%),0.6≤C_(i)<0.8的基本合理病例60例(46.15%),C_(i)<0.6的不合理病例32例(24.62%)。结论:采用加权TOPSIS法评估儿科美罗培南的合理应用是切实可行的,我院美罗培南的应用仍存在问题,应加强管理,促进美罗培南在儿科患者中的合理应用。

Objective:To discuss the evaluation system of pediatric meropenem to provide reference for its rational use in pediatrics.Methods:The standards of pediatric meropenem drug use evaluation(DUE)were constructed,and the weighted TOPSIS method was used to evaluate pediatric patients who used meropenem in the pediatrics department of our hospital from October 2020 to March 2021.Results:A total of 130 eligible cases were collected.According to their relative closeness to the optimal solution,38 cases(29.23%)were reasonable with C_(i)≥0.8,60 cases(46.15%)were basically reasonable with 0.6≤C_(i)<0.8,and 32 cases(24.62%)were unreasonable with C_(i)<0.6.Conclusion:It is reasonable and feasible to use weighted TOPSIS method to evaluate meropenem in pediatrics.There are still some problems in the use of meropenem in our hospital,so we should strengthen the management and urge it to the optimal solution.